Determining the mechanism of action of a novel cancer therapeutic by Ahmad, Mona




























In Partial Fulfillment 
of the Requirements for the  
Research Option in the 






































Dr. Ravi Bellamkonda, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
Dr. Jung Choi 
School of Biology 
Georgia Institute of Technology 
 
Dr. Joseph Montoya 
School of Biology 










 I would first like to thank Dr. Jennifer Munson for taking me under her wing and 
mentoring me through my years in lab. Without her guidance, I never would have learned 
so much about cancer.  Jenny was an amazing mentor, giving me the freedom to learn by 
myself, but always providing instruction exactly when I needed it. She helped me to 
become independent in my work, and without that experience, I would more likely not be 
where I am today.  
 I would also like to thank my lab family: Eleanor DeHitta, Rania Khan, Sydney 
Rowson, and Shalini Nemani. We were there for each other to help if we ever needed 
anyone to split cells or check an experiment. With their friendship and support, I was able 
to complete these experiments with smiles and laughter every day. Their different 
perspectives and advice for the future were also invaluable to me as I moved forward 
through college. 
 This thesis would never have been possible without Dr. Ravi Bellamkonda, and 
for that I am grateful. He allowed me to work in his lab and provided amazing advice to 
me about my future. I could not have been included in a better lab or learning 
environment, and I doubt I will ever be in such a lab again. 
 I want to thank my grandfather, Dr. Muhammad Ishaque, for instilling a love of 
learning in our family and for encouraging me to try research. Because of him, my 
mother, Dr. Naheed Ahmad, raised me to be curious about all things and gave me the 
skills I needed to be successful in the lab. Without the love, support, and knowledge that 
my family provided, I would not be here today 
 v 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iv 
LIST OF FIGURES vii 
SUMMARY viii 
CHAPTER 
1 CHAPTER 1: INTRODUCTION 1 
1.1 Background 1 
1.2 Specific Aims 5 
1.3 Literature Review 5 
2 CHAPTER 2: IMIPRAMINE BLUE LOCALIZATION 11 
2.1 Introduction 11 
2.2 Methods 11 
2.3 Results 11 
2.4 Discussion 12 
3 CHAPTER 3:  IN VITRO PROTEIN LEVELS 14 
3.1 Introduction 14 
3.2 Methods 14 
3.3 Results 15 
3.4 Discussion 16 
4 CHAPTER 4: IMIPRAMINE BLUE PROTEIN INTERACTIONS 17 
4.1 Introduction 17 
4.2 Methods 17 
4.3 Results 18 
 vi 
4.4 Discussion 20 
5 CHAPTER 5: DISCUSSION 22 
5.1 Overall Discussion 22 
5.2 Future Directions 23 
REFERENCES 25 
 vii 
LIST OF FIGURES 
Page 
Figure 1: IB is anti-invasive in vitro 2 
Figure 2: IB is anti-invasive in vivo 3 
Figure 3: Co-treatment of IB and Doxorubicin in vivo causes total remission of 
glioblastoma 4 
Figure 4: DB-FITC localizes to the nucleus in RT2 cells 12 
Figure 5: IB does not affect actin structures in astrocytes 16 
Figure 6: IB does not directly bind to actin 19 
Figure 7: IB binds to Nox4 splice variant 20 











Glioblastoma is an extremely invasive form of brain cancer, causing it to be very 
deadly even after administering therapy. The cells of glioblastoma invade the tissue 
surrounding the brain tumor, so that the cancer persists even when the tumor is removed. 
To address this problem, Imipramine Blue, a novel cancer therapeutic has been 
developed. The drug has been successful in halting invasion of cancer cells in vitro and in 
vivo, but its mechanism of action is unclear. From examining the normal mechanism of 
cell invasion, it seems reasonable to expect that Imipramine Blue binds to actin or one of 
its upstream regulators. To examine the mechanism of action, actin polymerization 
assays, immunocytochemistry, nuclear localization, and a magnetic bead binding assay 
were performed. The data from the actin polymerization assays shows that Imipramine 
Blue does not affect actin polymerization outside of the cell. The immunocytochemistry 
data confirms that Imipramine Blue does not affect the actin structures or upstream 
regulators in healthy cells, but changes the activity of these proteins in cancer cells. 
Imipramine Blue has been shown to localize to the nucleus in nuclear localization assays. 
Finally, the magnetic bead binding assay identifies a splice variant of Nox4, an upstream 
regulator, as the binding protein to the drug. Identifying the mechanism of action of 
Imipramine Blue ensures that researchers and doctors can confidently apply the drug to 











Glioblastoma is an extremely invasive and deadly form of brain cancer. The five 
year survival rate of a patient diagnosed with this cancer is only 35%. The cells of 
glioblastoma can reproduce quickly and tend to migrate along the white matter tracts of 
the brain, which causes the tumor as a whole to be invasive throughout. The popular 
treatment for glioblastoma is resection; this is when a surgeon removes the tumor from 
the brain tissue. However, this surgery adds only a year at most to the patient’s lifespan. 
The cells that have migrated away from the main body of the tumor eventually reproduce 
and grow into a new tumor, further damaging the brain.  Radiation is also ineffective as a 
treatment; if it is not aimed directly at the tumor, the surrounding brain tissue will be 
damaged, making radiation of the migrating cells impossible. Therefore, it makes sense 
that halting invasion of the tumor is a priority if doctors would like resection and 
radiation to be effective. 
 The Bellamkonda lab has identified a novel compound that is anti-invasive to 
cancer called Imipramine Blue, provided by the Arbiser lab at Emory University. During 
in vitro experiments, such as invasion assays, the compound was shown to halt invasion 
of the cancer cells after only 3 hours; imaging also proved that the cells lost their invasive 
structures during this time (Figure 1).  
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Figure 1: IB is anti-invasive in vitro. (A) Invasion assays were performed with RT2, C6, U87MG, and 
U87EGFRV3 cells. IB was found to decrease invasion by the greatest amount in RT2 cells, a rat 
glioblastoma cell line. (B) RT2 cells were treated with Imipramine Blue (drug), treated with 
cytochalasin D (actin inhibitor), or untreated. After 3 hours, cells were fixed with 5% 
paraformaldehyde and stained for the cytoskeleton (red) and the nucleus (blue). IB was shown to 
have similar effects to cytochalasin D, thus halting invasion. Adapted from Munson 2012. 
 
 
Imipramine Blue also shows promise as a cancer therapy through its in vivo studies. Rats 
that were inoculated with a brain tumor and then treated with Imipramine Blue displayed 
tumors that showed no migration or spreading; normal brain tumors will be very spread 
out and the body of the tumor will be difficult to find (Figure 2).  
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Figure 2: IB is anti-invasive in vivo. 3RT2RT1 glioma cells were inoculated into rats’ brains. The 
brain on the left has not been treated and the brain on the right has been treated with IB. Brain slices 
were stained for the tumor (green) and healthy tissue (red) and imaged using fluorescence 
microscopy. The brain on the left shows cell spreading past the tumor border, whereas the IB treated 
brain is more clustered and stays within the confines of the border. Adapted from Munson 2012. 
 
When the tumors underwent additional chemotherapy after Imipramine Blue treatment, 
all evidence of the glioblastoma disappeared in the brain (Figure 3). 
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Figure 3: Co-treatment of IB and Doxorubicin in vivo causes total remission of glioblastoma. Rats 
were given 3RT1RT2 tumors and underwent two separate treatments: one group had doxorubicin 
alone (right) and the other had a co-treatment of doxorubicin and IB (left). The DXR rats showed 
tumor regrowth after 180 days; the IB rats showed complete remission. Adapted from Munson 2012. 
 
 
These results are promising for the future of Imipramine Blue and highlight its potential 
as a cancer therapeutic.  
 While it is clear that Imipramine Blue can stop glioblastoma invasion, its 
mechanism of action is still unknown. Understanding how Imipramine Blue works is 
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important to show that it is truly not harmful to healthy cells in any way. This way, the 
drug can be tested in bigger animals with more confidence. Additionally, by 
understanding the mechanism of action of Imipramine Blue, researchers can know which 
others cancers the drug would potentially work on. Having one drug to treat multiple 
cancers would be advantageous because it is cost-effective. 
Using the experiments that the Bellamkonda lab has already done, a starting point 
for this project would be to examine the cells at the protein level. The cancer cells 
become noninvasive because their cytoskeletal structures changed through actin 
rearrangement. Therefore, it is necessary to study the proteins that contribute to 
migration, starting with actin. Other protein pathways that lead to actin rearrangement, 
such as the Nox4 pathway, are also important for study. Lastly, the proteins that lead to 
matrix degradation of the surrounding brain tissue are worth studying as well if 
intercellular proteins do not yield any results.  
1.2 Specific Aims 
1) Localize Imipramine Blue in RT2 cells in vitro 
2) Differentiate levels of select proteins in Imipramine Blue treated cells at various times 
3) Characterize specific Imipramine Blue binding protein 
 
1.3 Literature Review 
1.3.1 Introduction 
To fully understand how Imipramine Blue halts invasion, the literature discussing 
the invasive properties of glioblastoma must be examined. The invasive mechanisms of 
glioblastoma are well-established. By fully understanding the normal mechanism of 
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migration, it is possible to understand how Imipramine Blue disrupts it. In this review, I 
will summarize the literature describing the most common mechanisms of glioblastoma 
invasion, including chemical signals from the microenvironment and signals from within 
the cell itself. The research in this literature review will identify which proteins should be 
given priority in this study, based on how central they are to glioblastoma migration.  
 
1.3.2 Cytoskeleton Rearrangement 
A cell cannot migrate without actively rearranging its cytoskeleton. Non-invasive 
cells are typically spread out in every direction. Conversely, an invasive cell has 
protrusions coming from the cell body that help it to migrate. Yamaguchi and Condeelis 
(2007) thoroughly describe the importance of actin to cancer cell movement in their 
research. They show in their work that disrupting normal actin function in glioblastoma 
effectively takes away its ability to move. The results found from Imipramine Blue 
treatment mimic the results of this study: cells become rounded and lose all motility. 
When the cell migrates, the actin cytoskeleton must rearrange to create an invasive 
structure; these structures are identified by Yamaguchi and Condeelis as filopodia, 
lamellipodia, and specifically for cancers, invadopodia. The invadopodia can be seen as a 
protrusion from the cell, projecting into the extracellular matrix. The researchers also 
identify profilin and scinderin as active regulators of actin polymerization; these can stop 
or start the process of actin rearrangement
13
. Hall and Nobes (2000) explain that actin is 
regulated upstream by RhoGTPases, Src kinase, and NFκB. Disrupting the function of 
any of these upstream regulators causes similar results as those in Yamaguchi’s study.  
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It is clear from this research that actin is the most likely candidate for Imipramine 
Blue binding and disruption and a starting point for this study. Interfering with actin 
shows similar morphological results as the results obtained from Imipramine Blue 
treatment. The study will begin by examining actin and its regulators, profilin and 
scinderin. Following that, the upstream regulators identified by Hall and Nobes will be 
considered. If none of these prove to be the protein of interest, the study must broaden to 
look at proteins even farther upstream. 
 
1.3.3 NADPH Oxidase Signalling 
There is another class of proteins which causes the cell to migrate in conjunction 
with the actin family, called NADPH Oxidases, or the Nox family of proteins. Chen, 
Craige, and Keaney (2009) explain in their study of the Nox family that Nox proteins 
cause reactive oxygen species (ROS) to generate in the cell
1
. This is significant because 
ROS activate many signaling pathways relating to cell survival, namely cell migration. 
Because of the effects of ROS, cancer cells exploit Nox proteins to their advantage, 
improving their survival. The researchers categorize six types of Nox proteins: Nox1, 
Nox2, Nox3, Nox4, Nox5, and Duox1/Duox2, all which produce ROS in cancer cells. 
Chen and his collaborators found that the categories of Nox proteins are located in 
different membranes within the cell and that the location of the Nox protein determines 
its downstream effects. The membranes the Nox family can be on include the 
endoplasmic reticulum, the nucleus, the mitochondria, the outer cell membrane, or on 
individual endosomes
1
. The Nox proteins can affect actin rearrangement from all of these 
areas of the cell. One step in the research is to identify where Imipramine Blue is 
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localizing within the cancer cell; this way, if Nox is found to be the binding protein, it 
will be possible to identify its category. Recently, Goyal (2009) has shown that Nox can 
be found in cells as a “splice variant.” This means that the protein has been cleaved but 
still retains its function. Goyal’s research shows that these splice variants also have 
separate locations in the cell, further complicating the effort to narrow down the possible 
proteins in this study. For example, Nox4, identified by Munson (2011) as an important 
protein to study for glioblastoma, has five different splice variants which can be found in 
the endoplasmic reticulum, the nucleus, and the cytoplasm
6
. 
Nox proteins are worth a lot of study when trying to understand brain cancer 
because they are so central to cancer migration. The ROS they create activate many 
proteins that are crucial to beginning the invasion process. In a Nox study by Shono 
(2008), he shows that protein kinase C, protein tyrosine phosphatases, and mitogen-
activated protein kinase are all activated by ROS, which causes cells to become 
malignant and cancerous
12
. Nox4 has specifically been implicated by Li (2009) and 
Munson (2011) in causing many of the changes seen in glioblastoma; it is overexpressed 
in every stage of glioblastoma invasion. When Nox4 was knocked out in Li’s research, 
the glioblastoma became significantly less invasive and responded well to cancer 
therapies. In the same study, Nox4 was needed for creation of invadopodia
9
. It is clear 
that special attention should be given to Nox4 in the study of glioblastoma invasion  if 





1.3.4 Extracellular Matrix Detachment and Degredation 
Gimona (2008) has examined the extracellular environment in his study of cell 
movement. He found that the first step to cell invasion through the matrix is detachment 
from the extracellular matrix (ECM) and from other cells. Cells stay adherent to the ECM 
through focal adhesions, which interact with many other proteins to maintain adherence
5
. 
Demuth and Berens (2004) have identified the proteins as integrins, Src kinase, and focal 
adhesion kinase (FAK). These are regulated by RhoGTPase; Src kinase is also regulated 
by interacting with FAK
2
. They discovered that proteins work to maintain cell binding 
and change the internal structure of the cell by recruiting cytoskeletal proteins. Research 
by Friedl and Wolf (2009) examining cell migration has shown that FAK is 
overexpressed in many cancer types; the degree of overexpression correlates to the 
degree of malignancy. Src is similar in this property: overexpression correlates to 
malignancy. They realized that that turning these proteins off in the cell can halt 
invasion
4
. It is unclear from previous research whether Imipramine Blue stops the cell 
from binding to the extracellular matrix, or if it just does not allow the cell to rearrange 
internally. Therefore all of the proteins identified in the research characterizing cell 
movement through the matrix should be under scrutiny. 
For cells to continue invading through the extracellular matrix, it is necessary for 
them to degrade the matrix itself. A very broad study by Pullen and Fillmore has shown 
that this is most commonly done using matrix mettaloproteinases (MMPs). MMPs 
degrade membrane proteins such as collagen and gelatin, which hold the matrix together. 
Two types, MMP-2 and MMP-9, are extremely overexpressed in glioblastoma. In the 
study, an experiment demonstrated that MMP activity can be induced by a variety of 
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signals, including normal cells of the brain and that inhibiting MMP activity successfully 
halts invasion. 
 Since Imipramine Blue is able to halt invasion in vitro, where there is no 
collagen, gelatin, or laminin to break down, these are most likely not the proteins of 
interest for this study. However, preliminary experiments using laminin coated plates 
have shown similar results to experiments preformed without laminin. Therefore, MMPs 






IMIPRAMINE BLUE LOCALIZATION  
2.1 Introduction 
 To first understand how Imipramine Blue is halting invasion of cancer cells, we 
must first know where Imipramine Blue localizes in treated cancer cells. By attaching a 
fluorescent marker to Desipramine Blue, an analog of Imipramine Blue which has a 
conjugation site, we will be able to track the drug in the cell by imaging at different time 
points. Once we see where the drug acts in the cell, we can narrow down our host of 
proteins according to cell region (nuclear, mitochondrial, cytosolic, etc.) 
2.2 Methods 
2.2.1 Desipramine Blue Conjugation and Localization 
Desipramine Blue (DB) was conjugated to amine reactive FITC (Invitrogen) 
using the protocol provided. Conjugated DB was then encapsulated in liposomes in 
preparation for delivery. RT2 cells were seeded at 100,000 cells/ml in four 8 chamber 
slides. Each slide will undergo a different drug treatment (liposomal conjugated DB, free 
conjugated DB, free IB, untreated). Cells were then fixed with 4% paraformaldehyde at 
the following timepoints: 5 minutes, 15 minutes, 1 hour, 2 hours, 4 hours, 24 hours, and 
48 hours. Cells were stained with rhodamine phalloidin (Invitrogen) and DAPI before 
imaging. 
2.3 Results 
2.3.1 Imipramine Blue localizes to the nucleus of RT2 cells 
 Following treatment with DB, cells were imaged for FITC, DAPI (showing the 
nucleus), and rhodamine phalloidin (showing actin) at each timepoint mentioned. The 
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treatments imaged were the DB-FITC conjugate, free DB, free FITC (not shown) and a 
control. After imaging, we observed FITC overlapping with DAPI in the DB-FITC 
treatment; in other words, FITC was brightest in the nucleus (Figure 4). Additionally, the 
experiment showed that treatment with DB causes RT2 cells to lose their invasive actin 
structures (Figure 4). 
 
Figure 4: DB-FITC localizes to the nucleus in RT2 cells. DB was conjugated to a FITC tag and 
administered to RT2 cells in vitro. Cells were then stained for F-Actin (red), nucleus (blue), and DB-
FITC (green). Results showed that DB-FITC localizes to the nucleus; additionally, DB alone affects 
RT2 cells in a similar manner to IB. 
 
2.4 Discussion 
 The results of the experiment showed that Desipramine Blue localizes to the 
nucleus. This is evidenced by the images, which have a bright FITC overlap with DAPI, 
the nuclear stain (Figure 4). We can assume that DB has the same activity as IB in vitro 
because the experiment also showed that it causes the same rounding in cells as IB 
treatment does. Therefore, IB localizes to the nucleus in RT2 cells. Proteins in the 
nucleus are usually regulators of transcription; because of their activity, the results of this 
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experiment show that IB most likely binds to an upstream protein in the invasion 
pathway. Knowing where IB acts in the pathway can help us to choose specific proteins 




IN VITRO PROTEIN LEVELS  
3.1 Introduction 
 By using previously obtained microarray data and localization data, treated RT2 
cells will be stained and imaged for a host of select proteins. By imaging these cells at 
different time points, we will know the levels of proteins during different points in the 
action of Imipramine Blue. We will also be able to corroborate the microarray data and 
understand when Imipramine Blue begins to act on certain proteins. This data will help us 
narrow down our list of proteins to test for Imipramine Blue binding. 
 
3.2 Methods 
3.2.1 in vitro Immunocytochemistry  
Cells were seeded in three 96 well glass-bottom plates (200 µl/well) at 50,000 
cells/ml and incubated at 37°C in a 5% CO2 atmosphere. The cells were then treated with 
Imipramine Blue (5 mg/ml) for 0 hours, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 
6 hours, and 24 hours. After treatment, Imipramine Blue was removed and cells were 
washed with 1X PBS. Cells were then fixed using 4%  paraformaldehyde and stained 
using the following primary antibodies:  α-actin (1:100), scinderin (1:5 ug/ml), NFκB 
(1:100) , nox4 (1:100) (AbCam), profilin (1:100), rho-gdi (1:50) (Santa Cruz 
Biotechnology, Inc.), and acetylated microtubulin (1:200) (Invitrogen). After 24 hours, 
cells were stained with the following secondary antibodies: AlexaFluor 488 goat anti-
rabbit, and AlexaFluor 488 goat anti-mouse (Invitrogen). The cells were then stained with 
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1X DAPI and phalloidin (1:200) obtained from Invitrogen. Cells were imaged using a 
Zeiss LSM 510 NLO with META MPE.  
3.3 Results 
3.3.1 Protein levels in RT2 and U87 glioma become variable in the presence of IB 
 After treating RT2, U87, and astrocyte cell lines with IB, the cells were fixed at 
different time points and stained with FITC for a host of proteins. Our observations 
through imaging clearly showed that the brightness of certain proteins would change, 
showing upregulation or downregulation. Over time, α-actin, profilin, NFκB, acetylated 
microtubulin, and Nox4 became less bright. Scinderin and rho-gdi, however, became 
brighter with time. We were not able to observe the first protein to change brightness. 
 
3.3.2 IB does not alter actin formation in astrocytes 
 From observing the cell structure of IB treated cells in the assay, we could see that 
RT2 and U87 glioma became rounded and lost their invadopodia with time; astrocytes 
however were not affected and kept their shape after treatment. Staining for α-actin 
showed that the cytoskeleton of the glioma changed dramatically (Figure 5A). In 
addition, we went on to quantify the cell roundness in each treatment using Image J. We 
found that cell roundness in RT2 and U87 increased over time, but roundness in 
astrocytes did not increase at all (Figure 5B).  
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Figure 5: IB does not affect actin structures in astrocytes. (A) RT2, U87, and astrocytes were treated 
with IB and fixed at different time points. Cells were then imaged for F-Actin (green) and the nucleus 
(blue). RT2 and U87 show rounding after only 3 hours in response to IB treatment. Astrocyte 
cytoskeletons are unaffected, showing IB does not harm healthy cells. (B) Cell roundness was 
quantified from various images in the experiment. RT2 and U87 show increasing roundness with 
time, whereas astrocytes show very low roundness at all time points. 
 
3.4 Discussion 
 The result of the experiment showed that IB changes protein levels in vitro, 
thereby upregulating or downregulating them (Figure 5). All of the proteins were in the 
same pathway, leading from RhoGDI to actin. However, it is not clear which protein’s 
levels began to change. We also saw that the actin structures in the astrocytes were not 
affected by IB, meaning that IB has no affect on healthy cells or proteins. Our proteins of 
interest are likely mutated by the cancer, but we can still stain for them with normal 
antibodies. This experiment effectively confirmed that IB is cancer-selective and safe on 
healthy cells.  
 The data from this experiment also corroborated the microarray data obtained 
previously. The changes in upstream protein regulators cause changes in actin structures, 
making the ball like shape that is indicative of noninvasive cells.  
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CHAPTER 4 
IMIPRAMINE BLUE PROTEIN INTERACTIONS 
4.1 Introduction 
 Ultimately, we would like to find the specific protein that Imipramine Blue binds 
to so that we can fully understand it’s function. This way, we can be assured that it is safe 
to use in animal and human trials in the long term. By using Desipramine Blue and 
conjugating it to Dynabeads®, which are magnetic, we can treat cells and hopefully bind 
the protein of interest. Then, by using the Western Blot technique, we will be able to 
establish the protein which is responsible for binding to Imipramine Blue, and thus 
halting invasion of the cancer cell. Previous data form collaborators indicates that Nox4 
is likely the primary target for Imipramine Blue; because of this, we will stain the 
Western Blot for Nox4 in our experiments. 
 
4.2 Methods 
4.2.1 Actin polymerization and depolymerization assays  
The effect of Imipramine Blue on actin polymerization and depolymerization was  
tested using the Actin Polymerization Biochem Kit (Cytoskeleton, Inc.) using the 
protocol provided with the kit. Cytochalasin-D (Invitrogen), a known inhibitor of actin 
polymerization was used as a negative control in the actin polymerization assay; 
phalloidin (Invitrogen), which inhibits actin depolymerization, was used as a negative 
control during the actin depolymerization assay.  
4.2.2 Magnetic Bead Binding Assay 
Dynabeads (Dynal Biotech, Inc.) were conjugated to DB using the protocol 
provided. Control beads were also made by activating according to the protocol and 
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withholding DB. Protein extracted from RT2 cells was treated with both the conjugated 
and unconjugated beads. The sorted protein from the conjugated beads, the supernatant 
from the conjugated beads, the protein from the unconjugated beads, the supernatant from 
the unconjugated beads, and the unsorted protein were all tested using a Western Blot. 
Based on recent data from a collaborating lab, the blot was stained with Nox4 primary 




4.3.1 IB does not affect actin polymerization outside of cells 
 Although we saw that IB is cancer selective and does not affect the actin 
structures in healthy cells, we wanted to confirm that IB did not interact directly with the 
actin protein. Using the actin polymerization assay, we saw that actin polymerization 
outside of the cell was not affected by the presence of IB; the cytochalasin D control 
treatment showed a drastic decrease in actin polymerization. Conversely, we found that 
IB did not halt actin depolymerization in the actin depolymerization assay; phalloidin, 




Figure 6: IB does not directly bind to actin. Actin polymerization and depolymerization assays were 
performed using IB, cytochalasin D, and phalloidin. The actin polymerization assay showed that IB 
had no effect on actin polymerization outside the cell; cytochalasin  D, which halts actin 
polymerization showed slowed activity. IB also showed no effects on actin depolymerization; 
phalloidin however showed slowed depolymerization. Therefore, IB does not directly bind to actin. 
 
4.3.2 Western blotting shows IB binds a 30 kDa protein 
RT2 cells were first incubated with the DB-Dynabead conjugate to ensure that the 
cells underwent similar transformations to IB treatment. We observed that images taken 
after three hours showed similar actin morphology to IB treated cells; this morphology 
included cell rounding and loss of invadopodia. After performing the magnetic bead 
binding assay on RT2 glioma, a Western Blot was performed using the following 
treatments: beads alone, protein from unconjugated beads, protein before incubation with 
beads, the supernatant from pulled protein, and the pulled down protein itself. The blot 
was stained for Nox4 and showed no bands in any treatment except for the pulled protein 
at 30 kDa (Figure 7). The molecular weight of Nox4 is actually 70 kDa, indicating that 
the protein in question must be a variant of Nox4. Although Nox4 is present in RT2 and 
should have been stained in the protein before incubation treatment, we believe that the 
concentration of protein was greater after treatment with the beads, allowing for a 
stronger band.  
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Figure 7: IB binds to Nox4 splice variant. Desipramine Blue, an analog of IB, was conjugated to 
Dynabeads. The protein was then isolated using the conjugate and identified using a Western Blot. 
The results showed a band at 35 kDA, implicating Nox4D as the protein. 
 
4.4 Discussion 
 The first experiment verified that IB does not affect actin polymerization or 
depolymerization outside of the cell. Basically, the results mean that IB does not directly 
bind to or interact with actin when changing actin structures. This is clear because there 
are no upstream proteins in the actin polymerization assay. Therefore, we showed with no 
uncertainty that IB binds to an upstream protein. 
 The next experiment was done to find the specific binding protein, using the bead 
binding protein. We eventually decided to stain the Western Blot for Nox4 based on data 
from the Knaus lab at UCD showing that IB inhibits Nox4 activity. It was not clear if it 
was acting as a direct inhibitor, and we decided to find the answer using our Western 
Blot. The blot showed a band in the sorted protein column at 30 kDa; this result is odd 
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considering Nox4 weighs 75 kDa. Research by Goyal (2009) shows that Nox4 can be 
found as certain splice variants in cells. One of these, Nox4D, is 30 kDa, localizes to the 
nucleus, and has the same activity as Nox4. We believe that the protein from the Western 
Blot is Nox4D. This makes sense because Nox4D is a mutated protein, and may be the 






1.1 Overall Discussion 
 
 The project overall showed that IB binds to and effectively inhibits Nox4D 
activity in RT2 glioma cells. This splice variant is located in the nucleus, which was 
confirmed by Specific Aim 1. Inhibition of Nox4D will cause the changes that we 
saw in the experiment in Specific Aim 2. If Nox4D is inhibited, it will cause the 
amount of ROS in the cell to be decreased, also causing inactivation of NFκB. 
Without NFκB, the transcription of actin mRNA into G-Actin, and thus 
polymerization of G-Actin into F-Actin is lowered (Figure 9). Knowing this specific 
mechanism of action can help us to be sure that IB is safe for use. Considering that its 
primary binding protein is mutated, it can be invaluable as a cancer therapeutic, 
especially when compared to therapeutics that are more harmful to the body than the 
cancer itself.  
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Figure 8: Mechanism of action of IB. The data shows that IB halts the activity of Nox4. This binding 
in turn leads to downstream effects including lowered signaling from second messengers and lowered 
actin formation. In all, this leads to inhibition of invasion. Adapted from Munson 2012. 
 
1.2 Future Directions 
 
 Now that the mechanism of action of IB has been confirmed, it can hopefully be 
considered for use as a widespread cancer drug. In glioblastoma specifically, IB should 
begin to be tested in bigger animals; after that, it can be moved to human trials. 
 IB should also be tested in other cancer types and evaluated for its effectiveness in 
halting invasion in those types. If does halt invasion, the cancer should be tested for the 
presence of the Nox4D variant. However, drugs can have multiple targets, so it is 
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possible that IB can be binding to another protein. If IB can be used in multiple cancers, 
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